Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2021

Pre-clinical common data elements for traumatic brain injury
research: Progress and use cases
Michelle C. LaPlaca
Emory University

Stuart H. Friess
Washington University School of Medicine in St. Louis

et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
LaPlaca, Michelle C.; Friess, Stuart H.; and al., et, ,"Pre-clinical common data elements for traumatic brain
injury research: Progress and use cases." Journal of Neurotrauma. 38,10. . (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10403

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

JOURNAL OF NEUROTRAUMA 38:1399–1410 (May 15, 2021)
ª Mary Ann Liebert, Inc.
DOI: 10.1089/neu.2020.7328

Downloaded by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE St. Louis E-PACKAGE from www.liebertpub.com at 06/13/21. For personal use only.

Pre-Clinical Common Data Elements
for Traumatic Brain Injury Research:
Progress and Use Cases
}lya Bayir,5
Michelle C. LaPlaca,1,24 J. Russell Huie,2 Hasan B. Alam,3 Adam D. Bachstetter,4 Hu
6
6
5
Patrick F. Bellgowan, Diana Cummings, C. Edward Dixon, Adam R. Ferguson,2
Chantelle Ferland-Beckham,7 Candace L. Floyd,8 Stuart H. Friess,9 Aristea S. Galanopoulou,10
Edward D. Hall,4 Neil G. Harris,11 Bridget E. Hawkins,12 Ramona R. Hicks,13 Lindsey E. Hulbert,14
Victoria E. Johnson,15 Patricia A. Kabitzke,16 Audrey D. Lafrenaye,17 Vance P. Lemmon,18
Carrie W. Lifshitz,19 Jonathan Lifshitz,19 David J. Loane,20 Leonie Misquitta,6 Vahagn C. Nikolian,3
Linda J. Noble-Haeusslein,21 Douglas H. Smith,15 Carol Taylor-Burds,6 Nsini Umoh,22 Olga Vovk,6
Aaron M. Williams,3 Margaret Young,5 and Laila J. Zai23

Abstract

Traumatic brain injury (TBI) is an extremely complex condition due to heterogeneity in injury mechanism, underlying
conditions, and secondary injury. Pre-clinical and clinical researchers face challenges with reproducibility that negatively
impact translation and therapeutic development for improved TBI patient outcomes. To address this challenge, TBI Preclinical Working Groups expanded upon previous efforts and developed common data elements (CDEs) to describe the
most frequently used experimental parameters. The working groups created 913 CDEs to describe study metadata, animal
characteristics, animal history, injury models, and behavioral tests. Use cases applied a set of commonly used CDEs to
address and evaluate the degree of missing data resulting from combining legacy data from different laboratories for two
different outcome measures (Morris water maze [MWM]; RotorRod/Rotarod). Data were cleaned and harmonized to
Form Structures containing the relevant CDEs and subjected to missing value analysis. For the MWM dataset (358
animals from five studies, 44 CDEs), 50% of the CDEs contained at least one missing value, while for the Rotarod dataset
(97 animals from three studies, 48 CDEs), over 60% of CDEs contained at least one missing value. Overall, 35% of values
were missing across the MWM dataset, and 33% of values were missing for the Rotarod dataset, demonstrating both the
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feasibility and the challenge of combining legacy datasets using CDEs. The CDEs and the associated forms created here
are available to the broader pre-clinical research community to promote consistent and comprehensive data acquisition, as
well as to facilitate data sharing and formation of data repositories. In addition to addressing the challenge of standardization in TBI pre-clinical studies, this effort is intended to bring attention to the discrepancies in assessment and
outcome metrics among pre-clinical laboratories and ultimately accelerate translation to clinical research.
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Introduction

D

evelopment of novel therapeutics to treat diseases and disorders of the central nervous system (CNS) is an extremely
challenging research endeavor. The difficulty and complexity of
successful therapeutic translation is illustrated by the United States
Food and Drug Administration’s (FDA) relatively low approval rate
for new CNS drugs in recent years (e.g., 8% from 2010–2014).1
Research to develop novel pharmacological interventions for the
treatment of traumatic brain injury (TBI) faces similar challenges.
Despite decades of pre-clinical TBI research and demonstration of
successful treatments in animal models, the field is still plagued by
poor clinical translation.2,3 In fact, despite the success of many preclinical studies and over 30 clinical trials, no TBI drug treatments
have graduated out of phase III trials to FDA approval.2,4 This lack of
translation continues to spark an active international discussion in
which TBI researchers are seeking to develop strategies to improve
translation from bench to bedside. Among these considerations,
many elements of translational science are being actively considered, including improving clinical trial design,2 improving definition of patient heterogeneity,5 and improving the rigor and
reproducibility of pre-clinical studies.6
Indeed, there has been a clarion call from the biomedical research community to raise standards for pre-clinical research by
improving rigor, reproducibility, and transparency,7–11 and efforts
to do this for TBI research are ongoing.12–15 Specific areas for
research design attention include improving the statistical power of
pre-clinical studies, reducing risk of exaggerated effect sizes and
low reproducibility,16 improving internal and external validity in
pre-clinical research,17 and the use of techniques to limit bias.18
Similarly, better reporting and sharing of key experimental variables are needed to increase reproducibility and provide more robust pre-clinical platforms.12,13,19–21 Another concern raised with
pre-clinical research is that many animal studies typically have low
statistical power,16 and reporting of key methodological variables
is varied, with many studies not reporting those key variables.22–25
To this end, there have been several initiatives in pre-clinical research communities, including TBI,12 spinal cord injury (SCI),21
and epilepsy26–28 to develop common data elements (CDEs).
CDEs facilitate standardization of datasets and database creation, enabling investigators to systematically collect, analyze, report, and share data across the research community. A data element
(DE) is a logical unit of data pertaining to a single measure or piece
of information that supports a measure, such that each DE is reduced to a single parameter, with multiple attributes, or descriptors.
Expert consensus for a set of DEs that have common data structures
for a given research field gives rise to CDEs, which provide reference content standards and can be assembled into a data dictionary. CDEs are identified by a variable name that will be linked to
the piece of data in the dataset, in addition to other attributes, such
as a title, description, unit of measure, permissible values, type of
element (e.g., numeric, alphanumeric), instructions, and references.

Data collection Form Structures are then built from CDEs to facilitate systematic assembly of data. See Supplementary Table S1
for a glossary of related terms. CDE standards are intended to be
dynamic and can evolve over time, ultimately promoting consistent
and universal data collection and reporting.
In this report, we expand upon the previous TBI pre-clinical
CDE initiative12 to better define and harmonize experimental
variables and data across individual studies and among laboratories. Specifically, we provide updates on the development of preclinical TBI CDEs, making new data collection tools available for
the pre-clinical TBI research community, and demonstrate proofof-concept use case studies that examine data missingness across
multiple experiments from different laboratories. We posit that the
use of CDEs to more carefully define the experimental variables
will provide a standard lexicon for researchers and improve the
rigor, reproducibility and ultimately the translational potential of
pre-clinical research in TBI.
Methods
CDE development
Initial efforts in the pre-clinical TBI CDE initiative identified
167 CDEs describing animal characteristics, animal history, assessments and outcome measures, and pre-clinical TBI injury
models.12 Here, we further develop and expand upon these CDEs,
define new CDEs, provide the CDE Data Dictionary and Form
Structures online, and demonstrate the use of these tools in a
missing value analysis of two different multi-study datasets
(Fig. 1). Working groups of content experts were formed to develop
the CDEs and guide a utilization process. Three working groups
were formed: 1) General Health and Affective Disturbances; 2)
Cognitive and Motor Function; and 3) Large Animals Outcomes.
Each group had co-chairs and met bi-monthly for approximately 12
months, with monthly meetings of the chairs and agency facilitators. Some working group members were part of the previous
pre-clinical CDE initiative; new members were chosen for this
expanded effort to ensure further diversity of expertise. National
Institutes of Health (NIH) and Department of Defense representatives facilitated the process and also provided perspective from the
clinical CDE effort.29,30
Working group members focused on identification of data elements that are relevant to pre-clinical TBI studies by drawing
from their own expertise and the literature, specifically concentrating on the frequency of use among different research groups
and how often a particular outcome measure or variable appeared
in published studies. Where appropriate, pre-clinical CDEs were
defined in parallel with companion clinical CDEs, to maximize
translatability (e.g., Injury Elapsed Time). At least two working
group members collaborated on the initial draft and several rounds
of group discussion and edits were conducted. The resulting CDEs
were available for two rounds of public review (https://fitbir.nih
.gov/content/preclinical-common-data-elements) that led to additional revisions in response to suggestions from the research
community.
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FIG. 1. Pre-clinical Traumatic Brain Injury (TBI) Common Data Element (CDE) Working Group Workflow Process. Working groups
were formed to identify the most commonly used procedures in pre-clinical TBI research. The most commonly collected variables were
identified as well as those that were commonly used across experimental procedures. These variables were defined into CDEs and then
logical groups of CDEs were made into Form Structures (FS). Once FS were created, reviews of the CDEs prompted revisions, such as
clarification of permissible values or consistency with similar CDEs. Legacy data were cleaned and mapped to the CDEs and harmonized within FS. The final FS were validated in and uploaded to a data repository. Data can then be shared and analysis can be
performed. Further iterative changes to CDEs are made continually during the process. The demonstration of the platform using legacy
data is invaluable to the process and permits improvements to be made based on real-world scenarios.

FIG. 2. Pre-clinical Traumatic Brain Injury (TBI) Common Data Element (CDE) Groups and Form Structure Procedure. The CDEs
are described by a set of attributes (left) that described the data element, inform the user about the input format and permissible values,
units of measure and similar information necessary to ensure consistent data entry. In addition, there are instructions, guidelines, and
references as appropriate. CDEs are organized into several groupings, shown in the center. The Main Group is intended to go on every
form and considered essential to every pre-clinical study. The Animal and Study Metadata includes groups on Animal History, Animal
Characteristics, and All Tests Common. The Injury Models CDEs are organized by injury model type, but forms may contain other
elements, such as Animal History and All Tests Common. Form Structures can then be built from the various groups of CDEs. For
example, a FS for a study that uses fluid percussion injury and Morris water maze would be built from the building blocks in the various
forms. Color image is available online.
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The resulting set of 913 unique CDEs consists of data elements
from three general groups: Animal and Study Metadata, Injury
Models, and Assessments and Outcomes (Fig. 2). CDEs are described by 18 attributes (variable name, description, datatype,
permissible values, etc.). The Animal and Study Metadata CDEs
are comprised of a Main Group of eight CDEs that are intended to
be included in every form, Animal Characteristics (six CDEs),
Animal History (71 CDEs), and All Tests Common (e.g., test
equipment information, room environment variables) (84 CDEs;
Table 1). The remaining CDEs are distributed among the Injury

Models and the Assessments and Outcomes. For this effort, five
injury models were completed (205 CDEs) as well as CDEs for
General Health and Neurological Function (six assessments, 93
CDEs), Affective Disturbance: Depression/Anxiety (10 tests, 293
CDEs)/Social Interaction (five tests, 361 CDEs), Cognition and
Motor: Learning/Memory (seven tests, 306 CDEs)/Sensory/
Motor (eight tests, 199 CDEs), and Large Animal Outcomes
(three tests, 115 CDEs; Fig. 2). Note that there are repeated
(or reused) CDEs among the various tests due to cross cutting
common CDEs; therefore, the number of CDE from these groupings

Table 1. General Study and Animal Subject Metadata
Main group
Title

Short description

Permissible values

1

GUID

Autogenerated

2

Subject identifier number

3
4

Study protocol name
Injury date time

5
6

Animal species type
Animal sex type

7

Animal birth date

8

Animal subject injury
group assignment type

Global Unique ID, which uniquely identifies a
subject
An identification number assigned to the
participant/subject within a given protocol or
a study.
Name of study protocol
Date (and time, if applicable and known) of
injury
Type of animal species of being studied
Type of animal species sex as determined by
observation
Date (and time, if applicable and known) the
animal participant/subject was born
Type of injury group assignment for an animal
subject

Free-form text, alphanumeric
Free-form text, alphanumeric
Free-form text, ISO 8601
Mice; rats; ferrets; pigs; primates; drosophila
Male; female; other*
Free-form text, ISO 8601
Anesthesia controls; Injured; naive; sham
injured; other, specify*

Animal characteristics (select CDEs)
Title

Short description

Permissible values, value type

1

Animal strain type

Free-form text, alphanumeric

2

Animal genetic modifications

3

Animal vendor type

A free text describing a type of strain of animal
species
A free text describing animal genetic
modification(s)
Animal vendor type

Value of measurement of animal weight. Should
be used in combination with Animal weight
unit of measure.
The change in absolute body weight from day of
injury to time of measurement
Type of animal subject pre-injury housing
including individual or group housing
Type of anesthetic given to a subject

Free-form text, numeric{

Free-form text, alphanumeric
Archer Farms Inc.; Charles River; Harlan;
Jackson Labs; Sinclair Bio Resources;
Taconic; Thomas D. Morris Inc.; None;
Unknown; Other, specify*

Animal history (select CDEs)
1

Animal weight measurement
value

2
3

Change in body weight
measurement
Animal subject housing type

4

Anesthetic type

5

Anesthesia duration

6
7

Animal injury number
Animal injury total number

Duration of time (in minutes) of the subject
being anesthetized
The number of traumatic event
Number of injury exposures for a given subject

Free-form text, numeric{
Multiple; single; split cage housing; unknown;
other, specify*
Bupivacaine; chloral hydrate; diethyl ether;
isoflurane; ketamine;
ketamine/medetomidine; Ketamine/xylazine;
lidocaine; none; other, specify*
Free-form text, numeric
Free-form text, numeric
Free-form text, numeric

CDEs are shown by the variable name, short description, and permissible values, which are three of the 18 attributes. Main Group CDEs are given;
these CDEs are intended to be included in every Form Structure. Selected CDEs from the Animal Characteristics and Animal History groups are also
shown. Note that some CDEs that may fit in a particular CDE grouping (e.g., Animal Characteristics) are considered part of the required Main group (e.g.,
Animal Species, Animal Sex). *Other; Other,specify designation requires a corresponding CDE with ‘‘Variable Name Other.’’ {For CDEs needing a unit
of measure, there is a corresponding CDE for ‘‘Variable Name Unit of Measure.’’
CDEs, Common Data Elements.

Downloaded by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE St. Louis E-PACKAGE from www.liebertpub.com at 06/13/21. For personal use only.

PRE-CLINICAL TBI COMMON DATA ELEMENTS UPDATE
exceeds the count of 913. Collectively, the CDEs make up the preclinical CDE data dictionary, which is available through the CDE
Repository at the National Library of Medicine within the NINDS
collection (NLM: https://cde.nlm.nih.gov/form/search?selectedOrg=
NINDS&classification=Preclinical%20TBI; https://fitbir.nih.gov).
The Forms (or Form Structures, FS) are analogous to clinical
Case Report Forms (CRFs) and are comprised of selected CDEs,
with a corresponding data dictionary that defines the CDEs. At the
Form level, CDEs are designated as Required, Recommended, or
Optional, to indicate the level of need for data harmonization
among datasets. There are Categories/Groups in some of the FS to
organize related subsets of CDEs (e.g., Software and Scoring,
Testing Conditions). FS are created using the building blocks from
the Main group of CDEs and relevant CDEs from the Animal and
Study Metadata groups, Injury Models, and Assessments and
Outcomes (Fig. 2). Many CDEs appear in more than one FS to
maintain a common lexicon across FS, and therefore the total
number of CDEs among the 46 FS created is 1664 (Table 2). For
example, the Animal Characteristics FS contains CDEs from the
Main Group and the Animal Characteristics CDEs, for a total of 13
CDEs. Similarly, each of the Injury Models and Assessments and
Outcomes have FS with groups of CDEs specific to that model or
test as well as CDEs from the Main Group, Animal Characteristics,
Animal History, and All Test Common group (e.g., Light Dark
Cycle Type, Trial Number). For the purposes of community dissemination, the 46 FS created are posted in the CDE Repository for
download and use in several different export formats (e.g., REDCap,
FHIR, JSON) (https://cde.nlm.nih.gov/form/search?selectedOrg=
NINDS&classification=Preclinical%20TBI; https://fitbir.nih.gov).
Researchers can export forms as well as create forms from the
available CDEs and field codes from the NIH CDE repository
(www.youtube.com/watch?v=LowLJh29-4M&t=1s).
Use case dataset: Selection and characteristics
To demonstrate the utility of the CDEs, we gathered datasets
from several laboratories from working group members and colleagues and piloted the workflow process, from data cleaning,
harmonization, and submission, to export for analysis. Analysis
included two proof-of-concept use case studies: 1) rat studies from
multiple labs using different injury models (fluid percussion injury,
FPI; controlled cortical impact, CCI; and penetrating ballistic-like
brain injury, PBBI) and the same primary outcome measure
(Morris water maze, MWM); and 2) a smaller dataset that used the
same injury model (FPI) and the same primary outcome measure
(RotorRod or Rotarod). The selection criteria for the datasets included: 1) that the study was already published or derived from
published studies; 2) data were available in electronic format; 3)
rodent injury models covered in the CDEs were used; and 4) either
MWM or Rotarod was a primary outcome measure. There were six
different labs and seven different datasets, including the following:
1) MWM: five datasets for MWM, all rat studies, three injury models
(CCI, FPI, PBBI), total of 358 subjects, 44 total CDEs for each
dataset, with 1851 total cases (animals x behavior trials/animal) and
85,146 total values (cases x #CDEs); and 2) Rotarod: three datasets
for Rotarod/Rotor Rod, two mice and one rat, both FPI injury model,
total of 97 subjects, with 453 total cases (animals · behavior trials/
animal) and 21,744 total values (cases · #CDEs) and 48 total CDEs
(see Supplementary Table S2 for summary of lab information). We
refer to these datasets as legacy data.
Data cleaning and harmonization
Prior to uploading the data, legacy data underwent cleaning and
data harmonization according to CDE definitions. Cleaning included various procedures, such as a simple search and replace
(e.g., ‘‘rat’’ to ‘‘rats’’), spell check, removing extra spaces, etc. The
dates were converted to ISO 8601 format, and the injury elapsed
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time data were recalculated from hours to minutes to correspond
with the CDE definition. In addition, some reasonable extrapolations were done, mostly for behavioral tests dates. For example,
since the behavioral tests were all done at a specific number of days
post-injury, as defined in the study design, if we knew the date of
injury, and if the behavioral test dates were not available, we extrapolated these dates based on the study design information. Files
were manually checked for values that appeared incorrect (e.g., out
of normal range) and if confirmed wrong or inconclusive, were
removed from the submission. Legacy data were entered into the
appropriate spreadsheet (i.e., FS, comma-separated value [csv]
format), and harmonized to the corresponding CDEs. Harmonization entailed mapping (or matching) the collected data categories to
the appropriate CDEs and entering the values into the corresponding column in the spreadsheet. Some data pieces were further
separated into basic units to facilitate mapping to the simplest CDE
level (e.g., 50 mg/kg intraperitoneally is a dose quantity, a dose
unit, and a dose route).
Form generation and data submission
The finalized sets of CDEs for MWM and Rotarod were gathered
into the logical FS. The FS for MWM contained 44 CDEs, where 20
CDEs were created specifically to capture key parameters of the
MWM test and 24 CDEs were taken from the set of variables
commonly used across multiple studies (Supplementary Table S3).
The CDEs include, among others, injury group (e.g., injured, sham,
naı̈ve), time elapsed since injury, species, sex, injury date, tank
diameter, water depth, water and room temperature, platform
height, duration of each trial, swim speed, latency, and percent time
in target quadrant. Overall, for MWM, there were 6 CDEs associated with ‘‘data collected’’ (i.e., dependent variables), with the
remaining 38 CDEs from independent variables related to animal
and experimental descriptors. The number of rows assigned to each
subject equaled the number of days the animal underwent water
maze assessment, so that the latency to find the platform on each
day of testing was entered in a single column for the corresponding
CDE. For example, if there were 4 days of MWM acquisition
testing followed by a probe trial on Day 5, there were five rows for
each subject. Similarly, the set of CDEs in the Rotarod FS includes
48 CDEs, where 15 CDEs were created specifically to capture key
parameters of the Rotarod test, and 33 CDEs were taken from the
set of variables commonly used across multiple pre-clinical TBI
experiments (Supplementary Table S4). The Rotarod FS contained
three CDEs in the ‘‘data collected’’ category and 45 CDEs associated with animal and experimental independent variables.
Each animal subject was assigned a Globally Unique Identifier
(GUID), provided by Federal Interagency Traumatic Brain Injury
Research (FITBIR) Operations, that was entered into the FS in
addition to the subject ID that was given by the investigator. Once
the data were mapped into the FS and cleaned, the FS was validated
and submitted to the FITBIR demo site (a temporary workspace for
the working group and pilot study) using the validation and submission tools on the FITBIR website.
Statistical analysis
We determined how well CDEs aligned on each uploaded dataset by performing a descriptive missing value analysis (MVA
module; SPSS v.25, IBM), which analyzes the extent to which data
were complete, and the nature of the ‘‘missingness.’’21,31 Each cell
was categorized as ‘‘complete’’ if it contained a value within the
cell of the uploaded spreadsheet. Data cells were categorized as
‘‘missing values’’ if they did not contain a value within the cell in
the uploaded spreadsheet. This is the foundation of the statistical
method known as ‘‘missing values analysis’’ where the pattern of
missingness is characterized, and mitigation strategies can be devised to recover missing data, or fill in (impute), or estimate missing

Table 2. Form Structures
General study and animal metadata
1
2
3

Main group
Animal characteristics
Animal history

Common CDEs for all forms
Inherent animal features
Experimental measurements and conditions, pertaining to the animal

8
13
79

Fluid impact to dura mater, diffuse
Piston impact to dura mater, focal
Penetrating injury, focal to path
Shock tube, mimic blast overpressure
Blast overpressure

32
29
21
57
66

General impairment, health status
General impairment, health status, Injury severity
Injury severity, health status

11
4
8

Neurological function
Neurological function
Vestibular motor, assessment of consciousness

21
31
18

Anxiety
Anxiety
Depression
Depression, helplessness, despair-like, affect
Naturalistic, anxiety, repetitive-like behavior, obsessive compulsive behavior
Anxiety, depression, motor, activity level
Anxiety
Depression, despair-like, affect, anhedonia
Anxiety/PTSD
Depression, helplessness, despair-like, affect

35
35
18
22
34
71
13
13
19
33

Aggression,
Aggression,
Aggression,
Aggression,
Aggression,

76
95
79
32
79
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Animal injury models
1
2
3
4
5

Fluid percussion injury model
Controlled cortical injury model
Penetrating ballistic-like brain injury model
Advanced blast simulator ABS model
Blast-induced injury model

Animal assessments outcomes: general health
1
2
3

Body conditioning score
Change in body weight
Morbidity/mortality

Animal assessments outcomes: neurological status
1
2
3

Neurological deficit score
Neurological Severity Score (small animals)
Righting reflex

Affective disturbance: depression/anxiety
1
3
4
5
6
7
8
9
10

Elevated plus maze
Elevate zero maze
Forced swim yest
Learned helplessness
Marble burying
Open field test
Predatory odor test
Sucrose preference test
Startle response
Tail suspension

Affective disturbance: social interaction
1
2
3
4
5

Partition Test
Social Interaction Resident Intruder Test
Three-Chamber Test
Tube Dominance Test
Urine Open Field Test

impulsivity,
impulsivity,
impulsivity,
impulsivity,
dominance

dominance, impaired social interaction
Dominance, impaired social interaction
dominance, impaired social interaction
dominance, impaired social interaction

Cognition and motor: learning/memory
1
2
3
4
5
6
7

Alternating (Attentional) Set Shift
Barnes maze
Conditional Place Preference
Contextual Fear Conditioning
Morris Water Maze
Novel Object Recognition
Radial Arm Maze

Frontal lobe function, attentional function
Spatial learning and memory, working memory
Contextual learning, addiction
Associative learning (cue and context)
Spatial learning and memory, working memory
Recognition memory, working memory
Spatial learning and memory, Working memory

24
71
55
39
46
22
49

Motor function, balance
Gross motor function
Motor skills
Sensorimotor
Implicit learning, procedural learning, spatial learning,
perseverance, motor function
Motor coordination, balance, Motor skill learning
Sensorimotor, proprioception
Motor skills, balance

11
29
18
9
53

Neurological status and function
Motivation, social interaction
Memory, cognitive processing

26
71
18

Cognition and motor: sensory/motor
1
2
3
4
5

Angle Board/Inclined Plane
Beam Walk
Cylinder Test
Grip Strength
Hole Poke Test

6
7
8

Rotor Rod / Rotarod
Sticky Paper Test
String Test

48
22
9

Large animal assessments
1
2
3

Neurological Severity Scale (large animals)
Human Approach Test
Neurocognitive Test

The 46 Form Structures that were developed are shown here. The form category is given along with the form name, the general description, and
number of CDEs. Note that the total number of elements among all the forms (1664) is more than the number of unique CDEs (913) because of CDEs
used across forms.
CDEs, Common Data Elements, PTST, post-traumatic stress disorder.

1404

Downloaded by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE St. Louis E-PACKAGE from www.liebertpub.com at 06/13/21. For personal use only.

PRE-CLINICAL TBI COMMON DATA ELEMENTS UPDATE
values within a particular confidence interval.31 Each dataset
(MWM, Rotarod) represents a number of studies within and across
labs. As discussed above, the data were structured so that repeated
measures were on separate rows of the dataset. Thus, each animal
had multiple rows associated with it. Each of these rows are referred to in this missing values analysis as ‘‘cases.’’ To accurately
assess the extent of completion, all identifying/demographic values
that would not vary across time (e.g., sex) for each animal were
repeated. The level of completion was assessed in three dimensions: the number of variables that had complete data across cases,
the number of cases with complete data across all variables, and the
total number of values that were completed (variables · cases).
Finally, the number of variables in each dataset for which there
were no data across all cases was reported.
Results
Missing data analysis: Morris water maze
Analysis of data missingness across the full set of data elements
for MWM data pooled across the five contributing laboratories are
shown in Figure 3. Analysis across data elements revealed that 50%
of the MWM data elements were complete, indicating that a half of
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data elements (spreadsheet columns) contained at least 1 missing
value. Analysis of cases (individual animals at individual timepoints; spreadsheet rows) revealed that 100% of the animals had at
least one missing data element. Yet, when considering the total
number of values (data 1elements x cases), a minority of values
were missing (35.25%). Examination of the overall matrix of (data
elements · cases) revealed that several variables were not being
collected at all in these legacy studies. Out of 20 MWM specific
CDEs, five CDEs contained no data for all the MWM studies,
indicating that 25% of CDEs defined specifically for MWM were
not being used at all, including three intended for data collection
and two describing MWM test parameters or equipment specifics.
Out of 24 cross-cutting CDEs, eight had blank data across all
MWM studies (38%), including two from the Main group (animal
birthdate and injury date time), two from equipment info (test
computer and apparatus model), as well as elements for room illumination level, time point before injury, and alternative (other) elements. In addition, there were 11 distinct patterns of missingness
that could be identified in the MWM dataset. This suggests that many
of the workgroup-defined MWM data elements are not in common
use by the TBI labs participating in the current pilot study. However,

FIG. 3. Missing Values Analysis for Morris Water Maze (MWM) Studies. (A) Visualization of missingness from five MWM datasets.
Each column represents a data element, each row represents an animal at a particular experimental time-point (defined as a ‘‘case’’).
Thus, each individual animal is represented by multiple rows. (B) Summary of Missingness. Breakdown of missing and complete data
by variable, case, and value; 47.5% of variables were filled completely by all cases; 0% of cases were complete, meaning that in each
case, at least one variable had a missing value. When assessing all values across variables and cases in total, 38.2% were missing and
61.8% were complete. (C) Percent of missingness for each CDE category in the MWM form structure.
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there were a number of elements that were collected universally
across labs, suggesting feasibility of implementing CDEs for MWM
in legacy datasets. The missing percentage for each CDE in the
MWM missing value analysis is in Supplementary Table S3.
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Missing data analysis: Rotarod
Analysis of data missingness across the full set of data elements
for Rotarod data pooled across the two contributing laboratories are
shown in Figure 4. Analysis across data elements revealed that
39.6% of the Rotarod data elements were complete, indicating that
a majority (60.4%) of data elements (spreadsheet columns) contained at least one missing value. Analysis of cases (individual
animals at individual time-points; spreadsheet rows) revealed that
100% of the animals had at least one missing data element. Analysis of the total number of values (data elements · cases) revealed
that 33.18% were missing across the three studies. Examination of
the overall matrix (data elements · cases) revealed 6 different distinct patterns of missingness, and that several variables were not
collected. From the CDE use perspective, out of 15 Rotarod specific
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CDEs, only three had all blank data for all Rotarod studies, indicating that 20% of these CDEs were not used in legacy studies. Out
of 33 CDEs commonly used across multiple pre-clinical tests, eight
had blank data across all Rotarod studies, which is 24% of all the
CDEs in the Rotarod forms. Of the 24 elements that contained at
least one missing value, three were CDEs in the ‘‘data collected’’
category, including the Rotarod RPM value (100% missing), the
Rotarod mean distance value (53.6% missing), and the Rotarod
latency time (2% missing), with the other 21 missing CDEs being
variables associated with groups such as animal information (e.g.,
animal birthdate) and experimental variables (e.g., trial duration
value). The CDEs with 100% missing values included three Rotarod specific variables, five animal information variables, two test
parameter variables, two equipment information variables, and one
room environment variable. Overall, this analysis suggests that
most of the workgroup-defined Rotarod data elements were in
common use for this pilot study, although additional legacy datasets should be queried to establish consensus. The missing percentage for each CDE in the Rotarod missing value analysis is in
Supplementary Table S4.

FIG. 4. Missing Values Analysis for Rotarod Studies. (A) Visualization of missingness from 2 Rotarod studies. Each column
represents a data element, each row represents an animal at a particular experimental time-point (defined as a ‘‘case’’). Thus, each
individual animal is represented by multiple rows. (B) Summary of Missingness. Breakdown of missing and complete data by variable,
case, and value; 38.8% of variables were filled completely by all cases; 0% of cases were complete, meaning that in each case, at least
one variable had a missing value. When assessing all values across variables and cases in total, 41.9% were complete. (C) Percent of
missingness for each CDE category in the Rotarod form structure.
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Discussion
We present the development of CDEs for TBI pre-clinical research and demonstrate the feasibility and utility of managing and
sharing data using the CDE platform. Working groups met regularly and focused on refining previously defined data elements,
incorporating additional core CDEs, and creating new CDEs for
commonly used behavioral outcome measures. In selecting and
defining the CDEs, the working groups considered the level of
experimental detail that is commonly reported across studies,
variables necessary for improved reporting rigor, as well as details
that may enhance inter-investigator data harmonization moving
forward. The result was 913 CDEs and 46 forms, all of which can be
used by the TBI research community to analyze legacy data and for
design of prospective studies.
In order to demonstrate utility of the CDEs, we collected
seven pre-clinical datasets for two behavioral outcome measurements from six different laboratories and conducted a proofof-concept exercise to map legacy data to the CDEs, upload the
Form Structures to a data repository, and analyze the data for
missing values among the datasets. In both datasets, at least half
of the CDEs had at least one missing value and 100% of the
animal subjects had a least one missing CDE, which is not surprising given the number of CDEs in the FS (44 for MWM and 48
for Rotarod) and multiple trials per animal. When considering
all the elements (i.e., values) across a dataset (number of subjects · number of CDEs · number of trials), only 35% of the
MWM FS data elements were missing, and 33% of the Rotarod
FS data elements were missing, indicating that investigators
have a substantial common set of CDEs but that there are also a
number of elements identified by the working groups that were
not used or reported as part of the legacy dataset.
It is not surprising that any given laboratory does not include all
the data elements recommended by a group of peer experts.
Working group discussions focused on the ideal set of variables
for TBI studies, focusing on common behavioral tests. Development of a comprehensive data dictionary ensures that common
language is proposed to the research community. As an ontology
evolves refinement of the CDEs will ensure that unnecessary or
arbitrary data elements are removed and pertinent elements are
added. It should be noted that several variables restrict responses
to a set of pre-defined values (e.g., animal injury models, housing
conditions) to permit standardization of terms and ease of searches. In these cases, it is typical to include a companion ‘‘other’’
element with a free form text box to allow for nonstandard data
entry (e.g., AnimalHousingTyp and AnimalHousingTypOTH).
The MWM FS contained two of these (both with 100% missing
values) and the Rotarod FS contained five ‘‘other’’ CDEs, with
three of them having 100% missing values, inflating the true
missing elements slightly.
With respect to CDEs not being used consistently across labs in
this analysis, it is possible that the CDEs were not anticipated to be
used in the original study. Most of the CDEs in the FS were associated with independent variables, especially those describing the
test parameters, test conditions, and equipment. It is worthy to note
that the Rotarod datasets were mostly from the same laboratory
(two of three, or 88% of the cases), and while the percentage of
missing CDEs was lower than in the MWM dataset, likely due to
laboratory specific protocols, the percentage of missing values was
similar. The patterns of missingness enabled us to examine consistency among datasets as well as the degree of congruency between working group emphasis and actual use. These observations
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may provide a guide for further work to understand the sources of
missing data (e.g., protocol differences, differences in data retention standards across studies).
Missing value analyses can define and highlight numerous systematic patterns of missingness. With larger datasets it may be
possible to use advanced analytical tools like machine learning to
identify missing data patterns and discover the source of data
missingness to improve coherence across labs. There are many
tools for dealing with missing values among datasets.31–33 For
example, tools such as the Little’s test31 allow automated data
screening to determine whether missing data can be explained by
other key variables and thus data are ‘not missing at random’
(NMAR). If so, these key sources of missingness can then become
points for quality improvement in data collection protocols. On the
other hand, if data missingness is unrelated to variables of key
importance, data can be considered ‘‘missing at random’’ (MAR)
and it may be possible to use advanced permutation methods to
estimate missing values and fill in (impute) values within a specified margin of uncertainty as a preprocessing step prior to carrying
out further statistical analysis. If missing data patterns are completely uncorrelated to any other variable within a dataset, they can
be considered ‘missing completely at random’ (MCAR) which
allows for a wide range of statistical approaches that can help
harmonize data using various data-synthesis approaches (e.g.,
multiple imputation, expectation maximization). Large datasets
(e.g., 100 studies with 10,000 subjects) are required to begin these
analyses. While we chose to use a missing value analysis to demonstrate use of the pre-clinical CDEs on combined datasets, there
are several other possible analyses that could take advantage of
these tools (see CDE Use Cases box).

CDE Use Cases
Case 1: Reproducing methods between laboratories. A TBI
investigator is unable to reproduce the degree of MWM
deficits using the same injury model and species reported in
a previously published study. The investigator queries a
research database that uses CDEs and finds several TBI
studies using MWM. No differences were found in how the
experimental TBI was produced or cortical lesion volumes,
indicating a comparable injury severity, but it was
discovered that the published study utilized a 6ft diameter
water tank while the investigator’s tank was 3ft in diameter.
After switching to the larger size tank, the new MWM data
were then similar to the published study.
Case 2: Checking novelty. An investigator reads about an
interesting drug from another field and wants to determine
if it has been studied in TBI. After finding no published
citations, she searches a preclinical CDE database and
discovers unpublished findings that show no therapeutic
efficacy. She examines the CDEs closely and observes that
the treatment window may not have been optimal for the
target mechanism. The investigator designs a new
experiment based on this information
Case 3: Metaanalyses. An investigator is testing the
efficacy of a particular drug on cognitive performance after
several TBI preclinical studies published results using
different behavioral assays and dosing parameters with
varying degrees of post-injury efficacy. To gain statistical
power to detect drug efficacy, the investigator performs a
metaanalysis on the combined results from multiple studies
that have been uploaded into a CDE database.
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FIG. 5. CDE Use in Data Analytics. CDEs can work prospectively and retrospectively / independently. The top left scenario depicts a
user who may work prospectively with a CDE based structured system, while the user on the bottom left may use independent,
laboratory specific data collection systems, which are then harmonized with existing CDEs. These harmonized data can then be used by
a variety of big data platforms. The use of CDE based informatic systems in research can facilitate data harmonization, thus easing cross
study comparisons, data aggregation and meta-analyses, simplifying staff training and study operations, improving overall study
efficiency, and promoting interoperability between different systems. Color image is available online.

While we used the FITBIR platform for this feasibility study,
there are no plans to open up a pre-clinical FITBIR data repository, but rather we provide tools (CDEs, forms) that could be used
in an individual laboratory or with another data repository (e.g.,
www.odc-tbi.org; Fig. 5). In addition, the FITBIR platform has
recently developed a ‘‘Meta Study’’ option for the pre-clinical
TBI research community to enhance data sharing and transparency (https://fitbir.nih.gov). Using this platform, investigators can
enter information about a research project by selecting the
‘‘Create Meta Study’’ option and populating fields to define the
study attributes (published or unpublished; e.g., Model Type,
Therapeutic Agent, etc.). Study documentation and data may also
be uploaded, such as experimental protocols, data tables, and a pdf
of the associated publication for research that is published. In
addition, a URL can be added to specify the online location for
data that are stored in another data repository. Other Meta Study
features include the generation of a DOI (digital object identifier),
which can be used for reference and reporting purposes, and a
search tool that can assist users in locating studies with specific
attributes.
Pre-clinical TBI research has many potential sources of variability from animal models to behavior assay procedures, which
can be captured through the use of CDEs. The use of multiple
animal models in the TBI pre-clinical community can be advantageous to represent clinical heterogeneity but comes with an
enormous variability in injury model parameters among labs and
operators. There is a need to accurately and thoroughly report the
details of the injury model and animal procedures for induction of
TBI in order to identify potential confounders in the response.19,34
Sources of heterogeneity in injury response can also arise from
animal strain, animal vendor, and genetic and physiological
differences—all of which can be captured in CDEs. Other within
laboratory and between laboratory sources of variability (some
less studied), including husbandry conditions, procedure time of

day, protocol execution, lab environmental conditions, measurement
technique, and general procedural differences (e.g., length of
anesthesia) are also likely to affect experimental outcomes and,
if not reported, could reduce reproducibility of the results.
Designing studies in the context of CDEs and corresponding
forms for data collection will result in more thorough reporting
of methods, including experimental injury parameters and outcome measures.38 Better definition of variables will provide TBI
researchers with tools to evaluate the impact of experimental
factors that may be important to the research design, as well as to
consider key research design elements that may explain differences in results from study to study.39 However, it is acknowledged that rigor does not necessarily result in reproducibility, but
it does allow the research community to identify factors that may
explain heterogeneity.
Importantly, CDE creation is not intended to dictate how procedures and outcomes are performed or collected, but rather to
provide a set of standardized, flexible tools to assemble the data.
Over-standardization may contribute to results that may be more
reflective of differences between laboratories and animal phenotypes rather than genuine scientific findings.35 Some recent work
suggests that heterogeneity may improve reproducibility. In an
analysis of single- versus multi-laboratory studies across 13 different interventions in pre-clinical models of stroke, breast cancer,
and myocardial infarction, multi-laboratory studies predicted effect
size up to 42% more accurately.36 Thoughtful standardization of
some model parameters and careful implementation of deliberate
heterogeneity may improve reproducibility and validity of preclinical results.37
The use of CDEs within and across laboratories is not without
challenges. As we observed, mapping legacy data to defined CDEs
is time consuming and is largely a manual process. With respect to
data sharing, maintenance of data repositories is not trivial and
requires data science expertise and financial resources. In addition
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to FITBIR (https://fitbir.nih.gov), pre-clinical data repositories
such as the Alzheimer’s Preclinical Efficacy Database (AlzPED,
https://alzped.nia.nih.gov), the Open Data Commons for Spinal
Cord Injury (www.odc-sci.org), and the Open Data Commons for
Traumatic Brain Injury (www.odc-tbi.org) provide examples of
data sharing platforms. Citation of the original publication and
reference to the data location itself is essential to ensure proper
credit and encourage sharing of positive and negative data alike.
Data use agreements are commonly used in biomedical sciences
and can clearly designate terms for data ownership, transfer of
ownership, proper citation, and public use. Despite these hurdles,
the use of CDEs in pre-clinical research will ultimately facilitate
sharing and experimental standardization, and aid in compliance
with journal data reporting policies.
While the working group focused on small animal behavioral
outcomes, it is recommended that future efforts continue development of CDEs for large animal injury models, as such models
become more widely used (see Supplementary Fig. S1 for a pilot
missing value analysis in porcine TBI model). Large animals, such
as the pig, are a necessary piece of the translation pipeline and can
better model human neuroanatomy and physiology, compared with
rodents. Other domains that will require attention in CDE development include histopathology, physiological measurements (e.g.,
blood gases, blood pressure, heart rate, electroencephalogram,
sleep), biofluid biomarkers, imaging, pharmacokinetics, and molecular and neurochemical assays. The broader goal of the working
group was to continue the dialogue with the basic and clinical
research communities to maximize the impact of pre-clinical data
harmonization and guide the trajectory to purposeful translation.
In summary, it is expected that the development of CDEs for preclinical TBI research will help to establish a well-define lexicon for
the collection, reporting, and sharing of pre-clinical data with the
goal of enhancing rigor, reproducibility, and transparency and
to account for difference within and between laboratories. Better
reporting will facilitate comparison of results between studies,
duplication of published studies and confirmation of findings,
possibly revealing new interpretation and hypothesis generation.
The prospect of using the tools described here is expected to foster
large collaborative efforts that require data sharing, such as prospective multi-site studies, meta-analyses, and data-based modeling efforts, ultimately improving the translation of pre-clinical
findings to clinical studies and treatments for TBI.
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Bernard, C., Gorter, J.A., Gröhn, O., Lipsanen, A., Lukasiuk, K.,
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